Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AMAG Pharma Names Edward Myles as CFO | Contract Pharma
Promotions & Moves

AMAG Pharma Names Edward Myles as CFO

Previously served in various positions at Ocata Therapeutics

AMAG Pharmaceuticals has appointed Edward Myles as senior vice president, chief financial officer and treasurer of AMAG. In this position, Mr. Myles will assume responsibility for AMAG’s financial and capital markets activities and will oversee the accounting, tax, corporate finance and investor relations teams. Mr. Myles will report to Frank Thomas, president and chief operating officer, AMAG.

“We are pleased to have Ted join us as CFO,” said Mr. Thomas. “Ted is an accomplished executive with a proven track record of financial and operational leadership in the biopharmaceutical industry. His experience in corporate finance, coupled with various roles in accounting and investment banking earlier in his career, make Ted an important addition to the executive leadership team. He will play a critical role in our continued efforts to fund the growth of the company and to create additional shareholder value.”

Mr. Myles brings more than 20 years of public and private corporate finance and operational experience in the biotechnology, pharmaceutical and medical device industries. Prior to joining AMAG, he served in various positions at Ocata Therapeutics, Inc., most recently as chief financial officer and chief operating officer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters